JP2016538269A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016538269A5 JP2016538269A5 JP2016526156A JP2016526156A JP2016538269A5 JP 2016538269 A5 JP2016538269 A5 JP 2016538269A5 JP 2016526156 A JP2016526156 A JP 2016526156A JP 2016526156 A JP2016526156 A JP 2016526156A JP 2016538269 A5 JP2016538269 A5 JP 2016538269A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- subject
- composition according
- compound
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims description 73
- 150000001875 compounds Chemical class 0.000 claims description 53
- 150000003839 salts Chemical class 0.000 claims description 37
- 239000008194 pharmaceutical composition Substances 0.000 claims description 29
- 201000006938 muscular dystrophy Diseases 0.000 claims description 15
- 230000037396 body weight Effects 0.000 claims description 14
- 235000012054 meals Nutrition 0.000 claims description 10
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 claims description 8
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 claims description 8
- 206010007559 Cardiac failure congestive Diseases 0.000 claims description 6
- 206010019280 Heart failures Diseases 0.000 claims description 6
- 206010028289 Muscle atrophy Diseases 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 230000000694 effects Effects 0.000 claims description 6
- 210000003205 muscle Anatomy 0.000 claims description 6
- 201000000585 muscular atrophy Diseases 0.000 claims description 6
- -1 sachets Substances 0.000 claims description 6
- 229940124597 therapeutic agent Drugs 0.000 claims description 6
- 208000024891 symptom Diseases 0.000 claims description 5
- 208000031229 Cardiomyopathies Diseases 0.000 claims description 4
- 206010068871 Myotonic dystrophy Diseases 0.000 claims description 4
- 208000001132 Osteoporosis Diseases 0.000 claims description 4
- 239000003263 anabolic agent Substances 0.000 claims description 4
- 206010003119 arrhythmia Diseases 0.000 claims description 4
- 210000000988 bone and bone Anatomy 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 4
- 239000002552 dosage form Substances 0.000 claims description 4
- 208000021302 gastroesophageal reflux disease Diseases 0.000 claims description 4
- 239000002207 metabolite Substances 0.000 claims description 4
- 239000007909 solid dosage form Substances 0.000 claims description 4
- 239000003826 tablet Substances 0.000 claims description 4
- 229960003604 testosterone Drugs 0.000 claims description 4
- 230000005021 gait Effects 0.000 claims description 3
- 206010003694 Atrophy Diseases 0.000 claims description 2
- 201000006935 Becker muscular dystrophy Diseases 0.000 claims description 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 2
- 208000002177 Cataract Diseases 0.000 claims description 2
- 102100034239 Emerin Human genes 0.000 claims description 2
- 201000009344 Emery-Dreifuss muscular dystrophy Diseases 0.000 claims description 2
- 206010016654 Fibrosis Diseases 0.000 claims description 2
- 206010020772 Hypertension Diseases 0.000 claims description 2
- 206010058359 Hypogonadism Diseases 0.000 claims description 2
- 201000006347 Intellectual Disability Diseases 0.000 claims description 2
- 102100022745 Laminin subunit alpha-2 Human genes 0.000 claims description 2
- 201000009342 Limb-girdle muscular dystrophy Diseases 0.000 claims description 2
- 208000034819 Mobility Limitation Diseases 0.000 claims description 2
- 208000010428 Muscle Weakness Diseases 0.000 claims description 2
- 206010062575 Muscle contracture Diseases 0.000 claims description 2
- 206010028372 Muscular weakness Diseases 0.000 claims description 2
- 208000008589 Obesity Diseases 0.000 claims description 2
- 206010033799 Paralysis Diseases 0.000 claims description 2
- 206010035664 Pneumonia Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 206010043298 Testicular atrophy Diseases 0.000 claims description 2
- 230000006793 arrhythmia Effects 0.000 claims description 2
- 230000037444 atrophy Effects 0.000 claims description 2
- 201000010788 atrophy of testis Diseases 0.000 claims description 2
- 231100000871 behavioral problem Toxicity 0.000 claims description 2
- 201000006815 congenital muscular dystrophy Diseases 0.000 claims description 2
- 208000006111 contracture Diseases 0.000 claims description 2
- 208000029078 coronary artery disease Diseases 0.000 claims description 2
- 239000003246 corticosteroid Substances 0.000 claims description 2
- 238000002405 diagnostic procedure Methods 0.000 claims description 2
- 201000009338 distal myopathy Diseases 0.000 claims description 2
- 230000002526 effect on cardiovascular system Effects 0.000 claims description 2
- 230000004761 fibrosis Effects 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 201000000079 gynecomastia Diseases 0.000 claims description 2
- 208000019622 heart disease Diseases 0.000 claims description 2
- 230000003054 hormonal effect Effects 0.000 claims description 2
- 239000012535 impurity Substances 0.000 claims description 2
- 238000001727 in vivo Methods 0.000 claims description 2
- 230000006698 induction Effects 0.000 claims description 2
- 208000015181 infectious disease Diseases 0.000 claims description 2
- 230000001788 irregular Effects 0.000 claims description 2
- 239000008297 liquid dosage form Substances 0.000 claims description 2
- 239000007937 lozenge Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 230000020763 muscle atrophy Effects 0.000 claims description 2
- 208000010125 myocardial infarction Diseases 0.000 claims description 2
- 210000001087 myotubule Anatomy 0.000 claims description 2
- 235000020824 obesity Nutrition 0.000 claims description 2
- 230000001575 pathological effect Effects 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 239000000651 prodrug Substances 0.000 claims description 2
- 229940002612 prodrug Drugs 0.000 claims description 2
- 210000002307 prostate Anatomy 0.000 claims description 2
- 230000002685 pulmonary effect Effects 0.000 claims description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 claims description 2
- 208000023504 respiratory system disease Diseases 0.000 claims description 2
- 206010039722 scoliosis Diseases 0.000 claims description 2
- 230000003637 steroidlike Effects 0.000 claims description 2
- 210000002784 stomach Anatomy 0.000 claims description 2
- 231100001044 testicular atrophy Toxicity 0.000 claims description 2
- 235000018823 dietary intake Nutrition 0.000 claims 2
- 230000037406 food intake Effects 0.000 claims 1
- 235000012631 food intake Nutrition 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 238000000034 method Methods 0.000 description 57
- JRBMBHHDIDARDR-UHFFFAOYSA-N CN(Cc1ccccc1)C([N+](CCCO)(c(cc1)cc(C(F)(F)F)c1C#N)[O-])=O Chemical compound CN(Cc1ccccc1)C([N+](CCCO)(c(cc1)cc(C(F)(F)F)c1C#N)[O-])=O JRBMBHHDIDARDR-UHFFFAOYSA-N 0.000 description 3
- 0 C*([C@@](CO)(C(*1c(cc2*)ccc2C#*)=O)c(cc2)ccc2O)C1=O Chemical compound C*([C@@](CO)(C(*1c(cc2*)ccc2C#*)=O)c(cc2)ccc2O)C1=O 0.000 description 1
- 206010012205 Delayed puberty Diseases 0.000 description 1
- 206010049418 Sudden Cardiac Death Diseases 0.000 description 1
- 230000009194 climbing Effects 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361895832P | 2013-10-25 | 2013-10-25 | |
| US61/895,832 | 2013-10-25 | ||
| PCT/US2014/062178 WO2015061685A1 (en) | 2013-10-25 | 2014-10-24 | Methods for treatment of muscular dystrophies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016538269A JP2016538269A (ja) | 2016-12-08 |
| JP2016538269A5 true JP2016538269A5 (enExample) | 2017-12-07 |
Family
ID=52993619
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016526156A Pending JP2016538269A (ja) | 2013-10-25 | 2014-10-24 | 筋ジストロフィーの処置のための方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20160250188A1 (enExample) |
| EP (1) | EP3060206A4 (enExample) |
| JP (1) | JP2016538269A (enExample) |
| CN (1) | CN105979943A (enExample) |
| AU (1) | AU2014339917A1 (enExample) |
| BR (1) | BR112016009214A8 (enExample) |
| CA (1) | CA2928235A1 (enExample) |
| MX (1) | MX2016005287A (enExample) |
| WO (1) | WO2015061685A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2643856B1 (es) | 2016-05-24 | 2018-08-03 | Universidad Del Pais Vasco / Euskal Herriko Unibertsitatea | Triazoles para la regulación de la homeostasis de calcio intracelular |
| WO2018156801A2 (en) * | 2017-02-22 | 2018-08-30 | Bioincept, Llc | Peptides and methods of treating dystrophy-related disorders using the same |
| WO2019236677A1 (en) * | 2018-06-05 | 2019-12-12 | The Regents Of The University Of California | Methods for treating muscular dystrophies |
| EP3952849B1 (en) | 2019-04-12 | 2024-09-18 | The Regents Of The University Of California | Compositions and methods for increasing muscle mass and oxidative metabolism |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0715087D0 (en) * | 2007-08-03 | 2007-09-12 | Summit Corp Plc | Drug combinations for the treatment of duchenne muscular dystrophy |
| GB2463514C (en) * | 2008-09-11 | 2018-09-26 | Galapagos Nv | Imidazolidine compounds and uses therefor |
| ITBO20090078A1 (it) * | 2009-02-13 | 2010-08-14 | Consiglio Nazionale Ricerche | Composti per il trattamento del tumore alla prostata e procedimenti per la loro sintesi |
-
2014
- 2014-10-24 EP EP14856707.6A patent/EP3060206A4/en not_active Ceased
- 2014-10-24 CN CN201480070003.0A patent/CN105979943A/zh active Pending
- 2014-10-24 WO PCT/US2014/062178 patent/WO2015061685A1/en not_active Ceased
- 2014-10-24 MX MX2016005287A patent/MX2016005287A/es unknown
- 2014-10-24 CA CA2928235A patent/CA2928235A1/en not_active Abandoned
- 2014-10-24 AU AU2014339917A patent/AU2014339917A1/en not_active Abandoned
- 2014-10-24 US US15/031,139 patent/US20160250188A1/en not_active Abandoned
- 2014-10-24 BR BR112016009214A patent/BR112016009214A8/pt not_active Application Discontinuation
- 2014-10-24 JP JP2016526156A patent/JP2016538269A/ja active Pending
-
2018
- 2018-10-24 US US16/169,019 patent/US20190167640A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Srivastava et al. | Influence on alternate nostril breathing on cardiorespiratory and autonomic functions in healthy young adults | |
| JP2017513882A5 (enExample) | ||
| JP2015526458A5 (enExample) | ||
| JP2017528483A5 (enExample) | ||
| JP2016523862A5 (enExample) | ||
| JP2013544887A5 (enExample) | ||
| JP2017510624A5 (enExample) | ||
| JP2010540519A5 (enExample) | ||
| JP2021527090A (ja) | 老化関連神経変性の進行および／または発症を治療および／または予防するための方法および組成物 | |
| JPWO2020004675A5 (enExample) | ||
| JP2023513220A5 (enExample) | ||
| EP3137622A1 (en) | Methods of reducing decline in vital capacity | |
| ES2701675T3 (es) | Irisina para el cuidado y la prevención de la osteoporosis | |
| US20240139210A1 (en) | Treatment of nf-kb-mediated disease | |
| JP2016538269A (ja) | 筋ジストロフィーの処置のための方法 | |
| US20210161908A1 (en) | Preventative and therapeutic agents for sarcopenia | |
| JP4652689B2 (ja) | 骨再生を促進するカルモジュリンの使用 | |
| Eagle et al. | GP 1.08 Steroids in Duchenne muscular dystrophy (DMD): Natural history and clinical evaluation using the North Star Ambulatory Assessment (NSAA) | |
| Gutierrez et al. | Administration of glucocorticoids in boys with Duchenne muscular dystrophy | |
| Sarikaya et al. | Hypophosphatemic osteomalacia due to tenofovir-induced Fanconi syndrome in chronic hepatitis B patient | |
| JPWO2013051330A1 (ja) | ビダラビンによる心房細動治療 | |
| Hoffstein et al. | Pharyngeal structure and function as a determinant of sleep-related breathing disorders: a unifying hypothesis | |
| RU2613765C1 (ru) | Способ лечения спиноцеребеллярной атаксии | |
| US9763973B2 (en) | Agent for treating HTLV-I associated myelopathy | |
| CN1407892A (zh) | 间歇性跛行治疗药 |